Celgosivir

Add links
Source: Wikipedia, the free encyclopedia.
Celgosivir
Clinical data
Other names6-O-Butanoylcastanospermine; MDL-28574; MX-3253
Legal status
Legal status
  • Investigational
Identifiers
  • [(1S,6S,7S,8R,8aR)-1,7,8-Trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
JSmol)
  • CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O
  • InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m0/s1
  • Key:HTJGLYIJVSDQAE-VWNXEWBOSA-N

Celgosivir, in development by Migenix for the treatment of

glycoproteins. Celgosivir is well absorbed in vitro and in vivo, and is rapidly converted to castanospermine. Celgosivir has a novel mechanism of action (preventing the glycosylation of viral proteins by the host), and demonstrates broad antiviral activity in vitro.[1]

Clinical trials

Celgosivir is not efficient as a monotherapy for the treatment of HCV, but has demonstrated a synergistic effect in combination with

pegylated interferon alfa-2b plus ribavirin, both in vitro and in phase II clinical trials that last up to 1 year in patients with chronic HCV infection. Celgosivir may prove to be a valuable component for combination therapy and may help to prevent the apparition of drug resistance. Long-term toxicity studies are necessary to confirm the safety of celgosivir in humans.[1]

Although generally safe and well tolerated, celgosivir does not seem to reduce viral load or fever burden in patients with dengue fever.[2]

References

  1. ^
    PMID 19649930
    .
  2. PMID 24877997
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Celgosivir&oldid=1135772370"